Dronedarone/ranolazine - Gilead Sciences

Drug Profile

Dronedarone/ranolazine - Gilead Sciences

Alternative Names: Ranolazine/dronedarone

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Acetanilides; Anti-ischaemics; Benzofurans; Class III antiarrhythmics; Ischaemic heart disorder therapies; Piperazines; Small molecules
  • Mechanism of Action Partial fatty acid oxidation inhibitors; Potassium channel antagonists; Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Paroxysmal atrial fibrillation

Most Recent Events

  • 16 Mar 2017 Discontinued - Phase-II for Paroxysmal atrial fibrillation in USA, United Kingdom, Poland, Netherlands, Italy, Israel, and Germany (PO), because dronedarone/ranolazine was not listed on Gilead pipeline of March 2017
  • 10 May 2014 Final efficacy data from the phase II HARMONY trial in Paroxysmal atrial fibrillation released by Gilead Sciences
  • 31 Mar 2014 Gilead Sciences completes the phase II HARMONY trial in Paroxysmal atrial fibrillation in USA, Germany, Israel, Italy, Netherlands, Poland and United Kingdom (NCT01522651)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top